ACC | 心衰患者接受营养风险筛查,可减少不良心血管事件

2022-04-06 MedSci原创 MedSci原创

尽早进行营养干预,很有必要!

心力衰竭是各种心脏疾病的终末期,也是心脏疾病的严重阶段,高龄、心功能分级高、生活质量差和自我管理行为差等可能增加心力衰竭患者营养不良发生的危险。因此,尽早干预,维持患者营养状况很重要。

营养风险筛查即通过相应的方法和手段去预测患者因现有的或潜在的营养不良和代谢状况异常所导致相应临床结局的可能性,减少并发症发生率和缩短往院时间等,同时探讨进行营养治疗对临床结局的影响。

目前,2002 年营养风险筛查 NRS-2002)是一种简便易行的较客观的营养风险筛查方法,它具有较好的预测效度,内容效度,信度和可操作性,已被广泛推荐用于识别有营养不良风险的患者。然而, NRS-2002 营养不良风险筛查与心力衰竭 HF)预后之间的关联尚不明确。

近日,一年一度的第71届美国心脏病学会年度科学会议(ACC 2022)已拉开帷幕,今年以线上线下的形式召开。此次会议上,研究人员发表了一项NRS-2002 营养不良风险筛查与HF预后之间关联的研究。结果显示, HF 患者中,NRS-2002 可被视为一种有效的营养筛查工具,是不良血管事件(MACE)、再次住院和住院时间的独立危险因素。

该研究招募了2,830 HF 患者,并根据NRS-2002评分将患者分为高营养风险组和低营养风险组。主要终点包括主要不良心血管事件(MACE)(定义为1年随访期间的死亡、中风或再次住院),次要终点包括住院时间和再次住院。研究人员通过线性回归分析以验证 NRS-2002 与患者住院时间之间的关联,使用回归模型确定 NRS-2002 MACE、再住院和住院时间≥5 天的关系。

结果显示,在 2,830 HF 患者中,122 名被认为具有高营养风险(NRS-2002 ≥3),平均年龄为 64.3 岁,66.4% 为男性。在调整逻辑回归后,NRS-2002 MACE 和再住院的独立危险因素(P <0.001)。另外,较高的 NRS-2002 也与较长的住院时间相关。

同时,在风险模型中添加 NRS-2002 可以提高对终点的预测性(MACE0.672 [0.647 0.697] vs. 0.616 [0.590 0.643]P = 0.001;再住院: 0.678 [0.653 0.703] 0.618 [0.591 0.645]P<0.001; 住院时间≥5 天:0.708 [0.689 0.728] vs. 0.682 [0.662 0.702]P = 0.033)。在探索性分析中,NRS-2002 的预测价值在亚组中保持一致。

总之,对于HF患者,应尽早进行营养干预,缓解机体功能恶化,降低并发症的数量和严重程度。

原始出处

https://cattendee.abstractsonline.com/meeting/10461/search?query=%40ModeratedPoster%7EYes&type=session&view=appendToCards&initialSearchId=19588&searchId=19588

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958131, encodeId=d84d1958131ef, content=<a href='/topic/show?id=b34f88181a2' target=_blank style='color:#2F92EE;'>#营养风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88181, encryptionId=b34f88181a2, topicName=营养风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Mon Jan 30 22:38:45 CST 2023, time=2023-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643788, encodeId=05261643e88a8, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sat Jul 09 02:38:45 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326939, encodeId=506b132693941, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Apr 08 13:38:45 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373563, encodeId=eb0113e356356, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Apr 08 13:38:45 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209135, encodeId=dff1120913533, content=认真学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Thu Apr 07 07:12:22 CST 2022, time=2022-04-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958131, encodeId=d84d1958131ef, content=<a href='/topic/show?id=b34f88181a2' target=_blank style='color:#2F92EE;'>#营养风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88181, encryptionId=b34f88181a2, topicName=营养风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Mon Jan 30 22:38:45 CST 2023, time=2023-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643788, encodeId=05261643e88a8, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sat Jul 09 02:38:45 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326939, encodeId=506b132693941, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Apr 08 13:38:45 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373563, encodeId=eb0113e356356, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Apr 08 13:38:45 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209135, encodeId=dff1120913533, content=认真学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Thu Apr 07 07:12:22 CST 2022, time=2022-04-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1958131, encodeId=d84d1958131ef, content=<a href='/topic/show?id=b34f88181a2' target=_blank style='color:#2F92EE;'>#营养风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88181, encryptionId=b34f88181a2, topicName=营养风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Mon Jan 30 22:38:45 CST 2023, time=2023-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643788, encodeId=05261643e88a8, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sat Jul 09 02:38:45 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326939, encodeId=506b132693941, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Apr 08 13:38:45 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373563, encodeId=eb0113e356356, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Apr 08 13:38:45 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209135, encodeId=dff1120913533, content=认真学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Thu Apr 07 07:12:22 CST 2022, time=2022-04-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1958131, encodeId=d84d1958131ef, content=<a href='/topic/show?id=b34f88181a2' target=_blank style='color:#2F92EE;'>#营养风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88181, encryptionId=b34f88181a2, topicName=营养风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Mon Jan 30 22:38:45 CST 2023, time=2023-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643788, encodeId=05261643e88a8, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sat Jul 09 02:38:45 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326939, encodeId=506b132693941, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Apr 08 13:38:45 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373563, encodeId=eb0113e356356, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Apr 08 13:38:45 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209135, encodeId=dff1120913533, content=认真学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Thu Apr 07 07:12:22 CST 2022, time=2022-04-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1958131, encodeId=d84d1958131ef, content=<a href='/topic/show?id=b34f88181a2' target=_blank style='color:#2F92EE;'>#营养风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88181, encryptionId=b34f88181a2, topicName=营养风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Mon Jan 30 22:38:45 CST 2023, time=2023-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643788, encodeId=05261643e88a8, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sat Jul 09 02:38:45 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326939, encodeId=506b132693941, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Apr 08 13:38:45 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373563, encodeId=eb0113e356356, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Apr 08 13:38:45 CST 2022, time=2022-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209135, encodeId=dff1120913533, content=认真学习~, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Thu Apr 07 07:12:22 CST 2022, time=2022-04-07, status=1, ipAttribution=)]
    2022-04-07 xulv123

    认真学习~

    0

相关资讯

ACC/AHA/HFSA 2022:推荐SGLT-2抑制剂用于治疗心衰

无论糖尿病状况如何,DAPA-HF 和 EMPEROR-HF 试验都证明用 SGLT-2 抑制剂治疗 HFrEF 患者的益处,显示心力衰竭再住院率降低了 30%。

JAHA:抑郁症状与心衰住院事件

在基线时无CHD的个体中,抑郁症状与HFpEF事件住院有关,但与HFrEF或基线CHD无关。

心衰老年患者管理,这种治疗方式太重要了!

心衰的运动治疗,学术名称为“基于运动的心脏康复”,包括:有氧耐力阶段,抗阻力量训练阶段,心衰深度吸气训练阶段。

JAHA:中枢性呼吸暂停对女性心衰患者危害更大

在慢性HF患者中,中枢性呼吸暂停与女性相比男性发生不良事件的风险更高。

实验性心脏肌球蛋白激活剂omecamtiv mecarbil在心衰患者中对运动能力没有任何益处

实验性心脏肌球蛋白激活剂 omecamtiv mecarbil 在射血分数降低的心力衰竭患者 (HFrEF) 的 III 期 METEORIC-HF 试验中对患者运动能力没有任何益处。